The Zacks Analyst Blog Highlights Joby Aviation, Archer Aviation and Strata Critical Medical

For Immediate Release

Chicago, IL – September 5, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Joby Aviation JOBY, Archer Aviation ACHR and Strata Critical Medical SRTA.

Here are highlights from Thursday’s Analyst Blog:

Joby's Premium Valuation: Should You Buy, Sell or Hold the Stock?

Joby Aviation, a leading player in the electric vertical takeoff and landing (eVTOL) space, is currently considered relatively overvalued. In terms of price-to-book value, JOBY is trading at 12.35X, higher than the Zacks Transportation - Airline industry and peer Archer Aviation. Like Joby Aviation, Archer Aviation also has a Value Score of F.

JOBY’s P/B TTM vs. Industry & ACHR

The question regarding JOBY that naturally arises is whether it is worth overpaying for the transportation player. Let us delve deeper and analyze JOBY’s fundamentals to answer the question.

JOBY’s New Landmark with Autonomous Flight Technology

Recently, JOBY showcased its autonomous defense capabilities by completing a military exercise. As part of the Resolute Force Pacific, a department-level exercise led by Pacific Air Forces, Joby conducted a demonstration and validation of its Superpilot autonomous flight technology over the Pacific Ocean and Hawaii. The exercise saw the transportation company logging in excess of 7,000 miles of autonomous operations across more than 40 flight hours.

The demonstration was in sync with Joby’s long-term strategy to develop dual-use technologies and highlighted its ability to offer an autonomous solution for the U.S. government’s requirement for light intra-theater airlift. Joby’s latest success positions it well to compete for the future Department of Defense programs.

JOBY Nearing Commercial Operations

Joby aims to start carrying passengers in Dubai next year. As part of its efforts related to air taxi commercialization, Joby recently completed the acquisition of Blade Air Mobility’s urban air mobility passenger business. Following the closure, Blade has changed its name to Strata Critical Medical. The passenger operations will continue to be led by its founder and CEO, Rob Wiesenthal, as a wholly-owned subsidiary of Joby.

The acquisition provides Joby access to Blade’s established network of terminals and loyal flyers in key markets, such as New York and Southern Europe. As a result, Joby gets a ready-made market for the aircraft. The buyout may expedite Joby’s entry into commercial service with its eVTOL aircraft once certified. Moreover, the closure of the buyout is likely to provide Joby a head start over competitors like Archer Aviation. Apart from providing market access and scale, the buyout is likely to reduce costs for new vertiports.

As part of its push toward commercialization, Joby recently completed its first flight between two U.S. airports — Marina and Monterey, CA — operating alongside other aircraft in FAA-controlled airspace. This milestone marks significant progress in Joby’s path to commercial readiness, showcasing advancements in safety, operational performance, air traffic integration, and certification efforts.

Earlier in the year, Joby unveiled plans to expand operations. To this end, the transportation company announced the expansion of its site in Marina, CA, which will double its aircraft production capacity at that location. The expanded site will span 435,500 square feet, helping the company to scale up its commercial operations. Once operational, Joby expects the Marina site to be able to produce up to 24 aircraft per year as it races to launch air taxis.

Driven by its commercialization-related efforts, JOBY shares have performed exceedingly well lately, gaining in excess of 72% in the past 90 days, outperforming its industry as well as rival Archer Aviation.

Headwinds That Cannot be Ignored

Joby Aviation is unlikely to be profitable any time soon, as commercial operations have yet to start. The company’s negative return on equity further highlights its lack of profitability.

In its path toward commercialization, JOBY is unlikely to escape turbulence as it navigates regulatory approvals, infrastructure development and consumer adoption. In the absence of commercialization, there is no real demand for urban air mobility at present.

Only time will tell how the market and customer demand for eVTOLs will turn out to be. Public acceptance of eVTOLs as an alternative to traditional transport methods could face hurdles related to safety, noise and affordability concerns. Without widespread recognition, JOBY's growth potential may be constrained. Additionally, the risk of battery failure due to high voltage and thermal issues is highly likely for eVTOL aircraft.

JOBY a Risky Investment Now

Based on the write-up, we can safely conclude that the company’s long-term outlook is strong, given the brightness associated with the eVTOL market and some investors may be willing to accept the premium. However, its current stock price already reflects a lot of this optimism. With the company facing certain risks, like the absence of significant revenues and uncertainties related to commercialization, jumping in now might mean overpaying. The Wall Street average target price for Joby Aviation is $10.57, suggesting a 21% downside.

Despite the eVTOL-related optimism, JOBY, currently carrying a Zacks Rank #4 (Sell), looks like a stock to avoid rather than chase.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research